New MDA Educational Program Offers a Detailed View of SMA Treatment Landscape

MDA’s new Medical Education department was established in response to the growing need for clinician education in neuromuscular diseases. We are pleased to present our first CME-accredited webinar highlighting the treatment landscape for spinal muscular atrophy (SMA).

SMA is a neuromuscular disorder that often presents as hypotonia and weakness shortly after birth. SMA is characterized by the degeneration of motor neurons, leading to progressive muscle weakness; SMA type 1, the most common form, is likely to be fatal within the first two years of life. Recently approved gene-targeted therapies have the potential to prolong and improve patients’ lives.  

Recent developments in the SMA treatment landscape

Dr. Julie A. Parsons from the University of Colorado School of Medicine and Children’s Hospital Colorado and Dr. Claudia A. Chiriboga from Columbia University Irving Medical Center and New York-Presbyterian Hospital created a detailed presentation and participated in a recorded webinar that summarizes the recent developments in the SMA treatment landscape. This webinar will help physicians learn about rapidly changing treatment options in SMA and facilitate the integration of new treatments into the comprehensive management of patients with SMA. MDA invites clinicians in our community to use this resource to educate themselves and other providers, while earning part of their CME credits.

View the webinar here.

If you have questions or comments, contact For more educational programs and resources, visit

Please see CME Accreditation and Designation Statements and Disclosure Report within the webinar viewing platform. This program is supported in part by an educational grant from AveXis Inc.